Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care

Background: Recent clinical trial results reported that stereotactic radiotherapy (SABR) may improve survival for patients with oligometastatic (OM) cancer. Given that these results come from a phase II trial, there remains considerable uncertainty about this finding, and about the cost-effectivenes...

Full description

Bibliographic Details
Main Authors:	Adam J. N. Raymakers, David Cameron, Scott Tyldesley, Dean A. Regier
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Current Oncology
Subjects:	cost-effectiveness analysis cost-utility analysis economic evaluation radiotherapy SABR health technology assessment
Online Access:	https://www.mdpi.com/1718-7729/28/3/172

Similar Items

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
by: Faiez Al-Shafa, et al.
Published: (2019-06-01)

Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease
by: Dirk Mehrens, et al.
Published: (2021-06-01)

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
by: Julia Malone, BSC, et al.
Published: (2020-11-01)

Developments in Stereotactic Body Radiotherapy
by: Anoop Haridass
Published: (2018-12-01)

Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study
by: Bai Y, et al.
Published: (2018-05-01)

Organizing pneumonia after stereotactic ablative radiotherapy of the lung
by: Murai Taro, et al.
Published: (2012-08-01)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
by: Rodney E. Wegner, et al.
Published: (2019-05-01)

Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR)
by: Eleanor Clarke, et al.
Published: (2020-09-01)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
by: Dhaliwal, I., et al.
Published: (2022)

Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
by: Sundus Yahya, et al.
Published: (2018-07-01)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
by: Charlotte L. Deijen, et al.
Published: (2021-09-01)

Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer
by: Mix M, et al.
Published: (2019-12-01)

A decision tool for radiographer-led abdominal image-guided stereotactic ablative body radiotherapy – Experience from a single institution
by: Mairead Daly, et al.
Published: (2021-09-01)

IMMUNE EFFECTS OF STEREOTACTIC ABLATIVE RADIATION THERAPY IN PATIENTS WITH MALIGNANT TUMORS: LITERATURE REVIEW
by: A. Yu. Zozulya, et al.
Published: (2020-10-01)

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
by: David Pryor, et al.
Published: (2021-03-01)

Late metastatic presentation is associated with improved survival and delayed wide‐spread progression after ablative stereotactic body radiotherapy for oligometastasis
by: Xuguang Chen, et al.
Published: (2021-09-01)

Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy
by: E. Leung, et al.
Published: (2020-01-01)

Thermal Ablation versus Stereotactic Ablative Body Radiotherapy to Treat Unresectable Colorectal Liver Metastases: A Comparative Analysis from the Prospective Amsterdam CORE Registry
by: Sanne Nieuwenhuizen, et al.
Published: (2021-08-01)

Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity
by: Christy Goldsmith, et al.
Published: (2018-10-01)

Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy
by: Tobias Finazzi, et al.
Published: (2020-04-01)

Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases
by: John R. van Sörnsen de Koste, et al.
Published: (2021-10-01)

Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting
by: Cory eHeal, et al.
Published: (2015-06-01)

A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy
by: Ciara A. Lyons, et al.
Published: (2017-08-01)

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer
by: Dan Yang, et al.
Published: (2020-03-01)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
by: Rosario Mazzola, et al.
Published: (2019-04-01)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
by: Relinde I. Y. Lieverse, et al.
Published: (2020-06-01)

The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer
by: Shyama U. Tetar, et al.
Published: (2020-09-01)

Stereotactic ablative radiotherapy as single treatment for early stage non‐small cell lung cancer: A single institution analysis
by: Xiaoli Zheng, et al.
Published: (2021-03-01)

Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer
by: Adam Mutsaers, et al.
Published: (2017-06-01)

Can reducing planning safety margins broaden the inclusion criteria for lung stereotactic ablative body radiotherapy?
by: Wsam Ghandourh, et al.
Published: (2021-09-01)

Treatment of Early Stage Non-Small Cell Lung Cancer: Surgery or Stereotactic Ablative Radiotherapy?
by: Esengül Koçak Uzel, et al.
Published: (2015-03-01)

The changes of radiotherapy in Lithuania: infrastructure, utilization rate, and cost
by: Ramunė Mineikytė, et al.
Published: (2016-04-01)

Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function
by: C. Senger, et al.
Published: (2019-10-01)

Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review
by: Rodolfo Chicas-Sett, et al.
Published: (2019-05-01)

Current Understanding of Ablative Radiation Therapy in Hepatocellular Carcinoma
by: Mathew AS, et al.
Published: (2021-06-01)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
by: Myungsoo Kim, et al.
Published: (2014-01-01)

Complications from Stereotactic Body Radiotherapy for Lung Cancer
by: Kylie H. Kang, et al.
Published: (2015-06-01)

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
by: Nicholas Hardcastle, et al.
Published: (2019-09-01)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
by: Laila König, et al.
Published: (2020-02-01)

Out-of-field dose in stereotactic radiotherapy for paediatric patients
by: Lachlan Garrett, et al.
Published: (2021-07-01)